IL146565A0 - A pharmaceutical composition containing an antisense oligonucleotide that binds to insulin-like growth factor binding protein-5 - Google Patents

A pharmaceutical composition containing an antisense oligonucleotide that binds to insulin-like growth factor binding protein-5

Info

Publication number
IL146565A0
IL146565A0 IL14656500A IL14656500A IL146565A0 IL 146565 A0 IL146565 A0 IL 146565A0 IL 14656500 A IL14656500 A IL 14656500A IL 14656500 A IL14656500 A IL 14656500A IL 146565 A0 IL146565 A0 IL 146565A0
Authority
IL
Israel
Prior art keywords
seq
insulin
binds
tumors
pharmaceutical composition
Prior art date
Application number
IL14656500A
Other languages
English (en)
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of IL146565A0 publication Critical patent/IL146565A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14656500A 1999-07-19 2000-07-19 A pharmaceutical composition containing an antisense oligonucleotide that binds to insulin-like growth factor binding protein-5 IL146565A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14449599P 1999-07-19 1999-07-19
PCT/CA2000/000853 WO2001005435A2 (en) 1999-07-19 2000-07-19 Antisense therapy for hormone-regulated tumors

Publications (1)

Publication Number Publication Date
IL146565A0 true IL146565A0 (en) 2002-07-25

Family

ID=22508861

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14656500A IL146565A0 (en) 1999-07-19 2000-07-19 A pharmaceutical composition containing an antisense oligonucleotide that binds to insulin-like growth factor binding protein-5
IL146565A IL146565A (en) 1999-07-19 2001-11-19 A pharmaceutical preparation containing an antisense oligonucleotide that binds to the 5-protein compound of an insulin-like growth factor

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL146565A IL146565A (en) 1999-07-19 2001-11-19 A pharmaceutical preparation containing an antisense oligonucleotide that binds to the 5-protein compound of an insulin-like growth factor

Country Status (13)

Country Link
US (1) US7297684B1 (ko)
EP (1) EP1200579B1 (ko)
JP (1) JP5121106B2 (ko)
KR (2) KR100779752B1 (ko)
AT (1) ATE393220T1 (ko)
AU (1) AU772480B2 (ko)
CA (1) CA2375467C (ko)
DE (1) DE60038680T2 (ko)
HU (1) HU228465B1 (ko)
IL (2) IL146565A0 (ko)
NO (1) NO332388B1 (ko)
NZ (1) NZ516701A (ko)
WO (1) WO2001005435A2 (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR633101A0 (en) * 2001-07-13 2001-08-02 University Of Sydney, The Method
NZ577565A (en) * 2001-10-09 2010-10-29 Isis Pharmaceuticals Inc Antisense modulation of insulin-like growth factor binding protein 5 expressions
US6750019B2 (en) * 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
AU2003237616B2 (en) 2002-01-17 2007-07-05 The University Of British Columbia Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
KR101117673B1 (ko) 2002-08-21 2012-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
ES2345330T3 (es) 2002-10-02 2010-09-21 The University Of British Columbia Oligonucleotidos para el tratamiento del cancer de prostata y otros canceres.
US8722872B2 (en) 2002-10-02 2014-05-13 The University Of British Columbia Compositions and methods for treatment of prostate and other cancers
WO2005030260A1 (en) * 2003-10-01 2005-04-07 The University Of British Columbia Bispecific oligonucleotide for the treatment of cns malignancies
PT2444505T (pt) * 2004-07-23 2017-01-13 Pacific Edge Ltd Marcadores urinários para a deteção de cancro da bexiga
WO2008106781A1 (en) 2007-03-05 2008-09-12 The University Of British Columbia Treatment of squamous cell carcinoma with hsp27 antisense oligonucleotides and radiotherapy
JP5390179B2 (ja) * 2008-12-24 2014-01-15 花王株式会社 Ｉｇｆｂｐ−５発現抑制剤
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2090702A1 (en) 1990-08-28 1992-03-01 Michael C. Kiefer Insulin-like growth factor binding protein igfbp-5
JPH06503947A (ja) 1990-08-28 1994-05-12 カイロン　コーポレイション Ｉｇｆｂｐ―５をコードする遺伝物質
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression

Also Published As

Publication number Publication date
HUP0201868A2 (en) 2002-12-28
DE60038680D1 (de) 2008-06-05
DE60038680T2 (de) 2009-05-07
KR100856475B1 (ko) 2008-09-08
NZ516701A (en) 2004-11-26
KR20070036180A (ko) 2007-04-02
US7297684B1 (en) 2007-11-20
JP5121106B2 (ja) 2013-01-16
NO332388B1 (no) 2012-09-10
WO2001005435A2 (en) 2001-01-25
KR100779752B1 (ko) 2007-11-27
CA2375467C (en) 2013-10-29
HU228465B1 (en) 2013-03-28
ATE393220T1 (de) 2008-05-15
EP1200579B1 (en) 2008-04-23
AU6144500A (en) 2001-02-05
IL146565A (en) 2012-02-29
WO2001005435A3 (en) 2001-03-22
CA2375467A1 (en) 2001-01-25
NO20020259D0 (no) 2002-01-17
KR20020033735A (ko) 2002-05-07
EP1200579A2 (en) 2002-05-02
JP2003504418A (ja) 2003-02-04
NO20020259L (no) 2002-01-17
AU772480B2 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
EP1163254A4 (en) ANTISENSE THERAPY FOR TRPM-2
CA2046916A1 (en) Methods and compositions for treatment of cancer using oligonucleotides
IL146565A0 (en) A pharmaceutical composition containing an antisense oligonucleotide that binds to insulin-like growth factor binding protein-5
WO1998011211A3 (en) Method for using oligonucleotides having modified cpg dinucleosides
WO2000008141A2 (en) Short oligonucleotides for the inhibition of vegf expression
AU9092001A (en) Antisense insulin-like growth factor binding protein (igfbp)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy
US6071891A (en) Insulin-like growth factor 1 receptors (IGF-1R) antisense oligonucleotide cells composition
CA2389036A1 (en) Antisense modulation of integrin-linked kinase expression
Rubenstein et al. Antisense oligonucleotide intralesional therapy for human PC‐3 prostate tumors carried in athymic nude mice
Hung et al. Antisense oligodeoxynucleotides targeted against different regions of CyclinD1 mRNA may exert different inhibitory effects on cell growth and gene expression
WO1991003260A1 (en) Antisense oligonucleotides to c-abl proto-oncogene
EP1282641A4 (en) Cervical cancer suppressing protein in women, polynucleotide encoding it, cell transformed by polynucleotide, and method of suppressing proliferation of cancer cells using the expression vector
KR20020069392A (ko) 인간의 페록시레독신 ｉｉ 안티센스 서열 및 이의 용도
Luster et al. Modification of tumor cell proliferation and peptide hormone secretion
WO2001079505A3 (en) INHIBITION OF BONE TUMOR FORMATION USING ANTISENSE cDNA THERAPY
Sikora et al. Genetic drug activation strategies for breast cancer
韩峻松 et al. Inhibition of the growth of human hepatoma cell line both in vitro and in vivo by transducing CKI gene p21^(WAF-1) with GE7 targeting gene delivery system
US20080051362A1 (en) Antisense Therapy for Hormone-Regulated Tumors
KR20040008459A (ko) 피오에이치 1 유전자 또는 피오에이치 1 단백질을포함하는 암세포 성장 억제제, 이의 제조방법 및 이를이용한 암세포 증식 억제방법